Modern Glaucoma Therapy


Glaucoma is a sight-threatening eye disease caused by impaired ocular outflow leading to elevated intraocular pressure (IOP).


Traditional surgical interventions are still widely used, but they can be associated with numerous intraoperative and postoperative complications and safety issues, and are usually reserved for late stage glaucoma. Consequently, surgeons are increasingly heading to non-penetrating, bleb-free, and less invasive glaucoma surgery for their early or mid-stage patients. Minimally invasive glaucoma surgery (MIGS) is safer than conventional surgery, but they are not equally clinically effective.


Canaloplasty is a new and safe surgical intervention that addresses the trabecular meshwork, Schlemm canal, and collector channels – structures that control ocular outflow. Canaloplasty is proven to be efficient in lowering intraocular pressure, and has a high safety profile. The main advantages of canaloplasty over conventional glaucoma surgery (e.g. trabeculectomy) are the reduced risk for complications, the independence of bleb formation and no need for toxic antimetabolites.


canal_expander_circle The Stegmann Canal Expander® is the latest development in canaloplasty, and the first implantable device into Schlemm canal to treat effectively glaucoma. The Stegmann Canal Expander® is a powerful biocompatible, non-metal, non-gelatin micro-implant and was approved for the European market (CE mark 0124) in 2012.